Notably, elevated ARMC12 and MYC levels were also linked to poor outcome of adrenocortical sarcinoma, B-cell lymphoma, renal clear cell carcinoma, or breast tumor (Figure S7A-D). This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.